Chemed Corporation

Informe acción NYSE:CHE

Capitalización de mercado: US$5.6b

Chemed Crecimiento futuro

Future controles de criterios 1/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Chemed de 12.9% y 6.3% respectivamente, mientras que el BPA crecerá en un 15.5% al año.

Información clave

12.9%

Tasa de crecimiento de los beneficios

15.53%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare18.3%
Tasa de crecimiento de los ingresos6.3%
Rentabilidad financiera futuran/a
Cobertura de analistas

Low

Última actualización27 Apr 2026

Actualizaciones recientes sobre el crecimiento futuro

Analysts Are Updating Their Chemed Corporation (NYSE:CHE) Estimates After Its Third-Quarter Results

Oct 31
Analysts Are Updating Their Chemed Corporation (NYSE:CHE) Estimates After Its Third-Quarter Results

Recent updates

CHE: Ongoing Buybacks And Earnings Guidance Will Support Balanced Future Returns

Analysts now see Chemed’s fair value holding at $443, with updated assumptions for revenue growth of 6.52%, a profit margin of 12.54%, and a future P/E of 15.49x shaping their refreshed price target rationale. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares for $197.7 million, representing 3.65% of its shares under the long running buyback program announced in February 2011 (Key Developments).

CHE: Expanded Buybacks And Earnings Guidance Will Support Stronger Future Returns

Analysts have kept their price target for Chemed steady at $443. This reflects updated assumptions around slightly different revenue growth, profit margin and future P/E inputs that do not materially change their overall valuation view.

CHE: Expanded Buybacks And Higher Margins Will Support Stronger Future Returns

Analysts have maintained Chemed's price target at $443, citing updated assumptions for profit margin and forward P/E as key factors behind the reaffirmed view. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, with projected earnings per diluted share in a range of $23.25 to $24.25, excluding certain non cash items such as stock option expenses, tax benefits from stock option exercises, litigation costs and other discrete items (corporate guidance).

CHE: Revised Outlook And Ongoing Buybacks Will Shape Balanced Future Returns

Analysts have revised their price target on Chemed to $443.00 from $555.50, reflecting updated views on revenue growth, profit margins, and the P/E multiple they consider appropriate for the stock. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, projecting earnings per diluted share, excluding specified non cash and discrete items, in a range of $23.25 to $24.25 (company guidance).

Repositioned Hospice Mix And Aging Demographics Will Support Stronger Long Term Performance

Catalysts About Chemed Chemed operates VITAS Healthcare, a large hospice provider, and Roto-Rooter, a national plumbing and water restoration service business. What are the underlying business or industry changes driving this perspective?

CHE: Stable Margins And Expanded Buybacks Will Support Future Upside

Analysts maintained Chemed's price target at $555.50, citing unchanged views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News On February 13, 2026, Chemed increased its equity buyback authorization by US$300 million to a total of US$3.05 billion under its existing repurchase program (Key Developments).

CHE: Stable Margins And Consistent Assumptions Will Support Future Upside

Analysts have maintained their fair value estimate for Chemed at US$555.50 per share, with only small adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, resulting in a marginally updated price target narrative. Valuation Changes Fair Value: Kept unchanged at US$555.50 per share, indicating no revision to the central valuation output.

CHE: Share Buybacks And Margin Outlook Will Support Future Upside

Analysts now see Chemed's fair value at US$555.50, down from US$582.25. This reflects updated views on the discount rate, revenue growth, profit margin and future P/E assumptions.

Here's What Chemed's (NYSE:CHE) Strong Returns On Capital Mean

Jan 16
Here's What Chemed's (NYSE:CHE) Strong Returns On Capital Mean

Analysts Are Updating Their Chemed Corporation (NYSE:CHE) Estimates After Its Third-Quarter Results

Oct 31
Analysts Are Updating Their Chemed Corporation (NYSE:CHE) Estimates After Its Third-Quarter Results

Chemed Corporation (NYSE:CHE) Shares Could Be 38% Below Their Intrinsic Value Estimate

Oct 24
Chemed Corporation (NYSE:CHE) Shares Could Be 38% Below Their Intrinsic Value Estimate

Chemed Corp: Genius Of The Model Lies In Its Corporate Strategy

Oct 06

New Florida CON Sites Will Advance Home-Based And Hospice Care

Chemed’s modest price target increase to $582.25 reflects stable sentiment, as core metrics like future P/E and revenue growth remain virtually unchanged. What's in the News Increased equity buyback authorization by $300 million, bringing total to $2.75 billion.

Chemed Corporation (NYSE:CHE) Shares Could Be 23% Below Their Intrinsic Value Estimate

Jul 07
Chemed Corporation (NYSE:CHE) Shares Could Be 23% Below Their Intrinsic Value Estimate

Chemed Corporation's (NYSE:CHE) Business Is Yet to Catch Up With Its Share Price

Jun 18
Chemed Corporation's (NYSE:CHE) Business Is Yet to Catch Up With Its Share Price
User avatar

Strategic Acquisitions And Operational Efficiencies Set To Propel VITAS And Roto-Rooter Forward

Strategic acquisitions, such as Covenant Health, and aggressive hiring in VITAS are poised to enhance Chemed's revenue and net margins through improved operational efficiency.

Chemed Remains A Buy On Long-Term Economics

Aug 16

Previsiones de crecimiento de beneficios e ingresos

NYSE:CHE - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/20283,015N/AN/AN/A1
12/31/20272,8593273464224
12/31/20262,6922953213914
3/31/20262,541260377444N/A
12/31/20252,530265325388N/A
9/30/20252,531279360420N/A
6/30/20252,512290371427N/A
3/31/20252,489309315366N/A
12/31/20242,431302368417N/A
9/30/20242,377302313361N/A
6/30/20242,336301253300N/A
3/31/20242,293283302354N/A
12/31/20232,264273273330N/A
9/30/20232,225245259322N/A
6/30/20232,187226280345N/A
3/31/20232,165240208269N/A
12/31/20222,135250253310N/A
9/30/20222,129262220273N/A
6/30/20222,141277284334N/A
3/31/20222,142267249303N/A
12/31/20212,139269250309N/A
9/30/20212,132308271332N/A
6/30/20212,121303283344N/A
3/31/20212,091329450507N/A
12/31/20202,080319430489N/A
9/30/20202,069271410466N/A
6/30/20202,021263413470N/A
3/31/20201,992231258317N/A
12/31/20191,939220N/A301N/A
9/30/20191,874209N/A294N/A
6/30/20191,837201N/A275N/A
3/31/20191,806205N/A296N/A
12/31/20181,783206N/A287N/A
9/30/20181,753206N/A202N/A
6/30/20181,727190N/A183N/A
3/31/20181,700113N/A159N/A
12/31/20171,66798N/A162N/A
9/30/20171,64276N/A198N/A
6/30/20171,61767N/A162N/A
3/31/20171,592114N/A197N/A
12/31/20161,577109N/A135N/A
9/30/20161,572106N/A187N/A
6/30/20161,566108N/A175N/A
3/31/20161,557111N/A166N/A
12/31/20151,543110N/A172N/A
9/30/20151,524110N/A172N/A
6/30/20151,496106N/A135N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (12.9% al año) de CHE es superior a la tasa de ahorro (3.4%).

Beneficios vs. Mercado: Se prevé que los beneficios (12.9% al año) de CHE crezcan menos que el mercado US (15.8% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de CHE crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (6.3% al año) de CHE crezcan más despacio que el mercado de US (11.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 6.3% al año) de CHE crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de CHE se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/01 11:00
Precio de las acciones al final del día2026/05/01 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Chemed Corporation está cubierta por 10 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Adam FeinsteinBarclays
Joanna Sylvia GajukBofA Global Research
Peter MartinCitizens JMP Securities, LLC